We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600
Open access books available

177,000
International authors and editors

195M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Therapeutic Drug Monitoring of Antiepileptic Medications

Matthew D. Krasowski
University of Iowa Hospitals and Clinics, United States

1. Introduction

Medications used to treat and prevent seizures (antiepileptic medications, AEMs) have been commonly managed by therapeutic drug monitoring (TDM) to optimize efficacy and avoid toxicity (Neels et al., 2004; Patsalos et al., 2008). TDM has been applied mostly to the first-generation AEMs that have been used clinically in the United States and Europe for several decades, namely carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone, and valproic acid. First-generation AEMs generally have significant inter-individual variability in their pharmacokinetics (absorption, distribution, metabolism, and excretion) and low therapeutic indices. Two randomized, controlled studies of AEM TDM showed that practitioners often apply information from TDM incorrectly (Fröscher et al., 1981; Januzzi et al., 2000). Consequently, improved education of medical practitioners on TDM is important for the future.

In the last twenty-five years, 14 new AEMs have entered the market in the United States and/or Europe (LaRoche & Helmers, 2004a,b; Patsalos, 1999). These drugs are sometimes characterized as second- or third-generation AEMs and include the following drugs: eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. Eslicarbazepine acetate, lacosamide, rufinamide, and stiripentol have not yet been approved in the United States. In contrast to the first-generation AEMs, the newer agents generally (although not always) have wider therapeutic ranges and less adverse effects. This chapter focuses on TDM of AEMs in treatment of epilepsy, emphasizing whether the pharmacokinetics and clinical profile of the drug make TDM useful. AEMs are sometimes used to treat disorders other than epilepsy such as trigeminal neuralgia, fibromyalgia, and migraine headaches (Johannessen Landmark, 2008; LaRoche & Helmers, 2004a).

There are several main challenges in TDM of AEMs (Patsalos et al., 2008). First, there are no simple diagnostic or laboratory tests for seizure disorders such as trigeminal neuralgia, fibromyalgia, and migraine headaches (Johannessen Landmark, 2008; LaRoche & Helmers, 2004a). The electroencephalogram (EEG) is useful for diagnosis of seizure disorders but is too labor-intensive for long-term patient observation. Second, seizures often occur unpredictably, sometimes with long periods of time between episodes. Lastly, the toxicity of AEMs can resemble neurologic disease, sometimes leading to inappropriate escalations of medication therapy even when the dose is actually too high.

One of the most basic assumptions of TDM is that the concentration of drug being measured correlates with the concentration at the target site of action (e.g., brain tissue). TDM of AEMs
is usually performed on plasma or serum, or occasionally on some other body fluid such as saliva. TDM is difficult to apply when there are factors (e.g., irreversibility of action, drug tolerance) that lessen the correlation between clinical effect and serum/plasma concentration. AEMs with active metabolites also present a special challenge for TDM. For drugs with active metabolites (e.g., oxcarbazepine, primidone), TDM can include measurement of the concentrations of both parent drug and its metabolite(s) or just of the metabolite(s).

TDM of AEMs in saliva has not yet been widely applied (Liu & Delgado, 1999), but has been studied for ten drugs: carbamazepine (Ruiz et al., 2010; Tennison et al., 2004), gabapentin (Benetello et al., 1997; Berry et al., 2003), lamotrigine (Inceayir et al., 2007; Malone et al., 2006; Ryan et al., 2003), levetiracetam (Grim et al., 2003; Guo et al., 2007; Mecarelli et al., 2007), oxcarbazepine (Cardot et al., 1995), phenobarbital (Tennison et al., 2004), phenytoin (Tennison et al., 2004), topiramate (Miles et al., 2003), valproic acid (al Za'abi et al., 2003), and zonisamide (Kumagai et al., 1993). Of these ten drugs, gabapentin and valproic acid are clearly unsuited for salivary concentration analysis. Gabapentin shows low concentration in saliva versus plasma (salivary concentrations are only ~5-10% that of serum or plasma) and valproic acid has poor correlation between serum and salivary concentrations. Monitoring of salivary concentrations of AEMs has clear appeal in some patient populations, especially in the pediatric and geriatric populations. One study showed that salivary samples can be collected by the patient and mailed to a clinical laboratory without loss of sample integrity (Jones et al., 2005).

2. Application of TDM to AEMs

The most common reason to employ TDM for AEM therapy is that the drug shows unpredictable and/or variable pharmacokinetics, often related to differences in drug metabolism (Bialer, 2005; Perucca, 2006). Variability in pharmacokinetics may also occur due to alterations in drug absorption or distribution. Metabolism of AEMs may vary due to impaired organ function (typically kidney or liver), genetic factors, or drug-drug interactions. Many of the AEMs are metabolized by hepatic enzymes including cytochrome P450 (CYP) enzymes such as CYP3A4 and CYP2C9. A number of drugs are known to increase (induce) the expression of hepatic drug-metabolizing enzymes. Well-known inducers include carbamazepine, phenobarbital, phenytoin, rifampin (tuberculosis drug) and St. John’s wort (herbal antidepressant) (Komoroski et al., 2004; Skolnick et al., 1976; Van Buren et al., 1984). In patients taking AEMs, the co-ingestion of liver enzyme inducers can lead to inappropriately low serum/plasma concentrations of the AEM if dose adjustments are not made. Some drugs may inhibit metabolism of AEMs, often by acting as antagonists of CYP enzyme activity, potentially leading to excessively high concentrations of drug unless the dose is reduced appropriately. Valproic acid inhibits multiple liver enzymes and has been well-documented to cause drug-drug interactions with other AEMs, which often requires careful TDM when valproic acid is used in multi-drug regimens to treat epilepsy (Neels et al., 2004). AEMs may be used in patients with some degree of renal impairment which can affect AEM pharmacokinetics by decreased clearance, or by removal of drug during dialysis procedures. In general, AEMs with low degrees of plasma protein binding are cleared more effectively by dialysis than AEMs that are highly protein bound (Lacerda et al., 2006).

Special considerations apply to TDM of AEMs that are highly (> 90%) bound to serum proteins. For these AEMs, monitoring of unbound (free) concentrations may be clinically
useful (Dasgupta, 2007). Serum protein concentrations of drug can vary due to factors such as drug interactions, liver disease, pregnancy and old age. Co-administered medications (e.g., valproic acid) or endogenous substances can displace drugs from serum protein binding sites, increasing free drug concentrations. Uremia, typically secondary to renal failure, can also displace AEMs from serum protein binding sites. Free drug concentrations can be measured by preparing an ultrafiltrate of plasma (e.g., by centrifugation through a membrane) and then analyzing the concentration of drug. The main technical challenge is that free drug concentrations may be substantially lower than total drug concentrations in drugs that are highly bound to plasma proteins. Therefore, analytical methods to measure free drug concentrations need to have lower limits of quantitation than methods to measure total drug concentrations. Analytical methods used to measure total drug concentrations may have insufficient analytical sensitivity for free drug analysis (Dasgupta, 2007). A further practical challenge is that the ultrafiltration process needed for free drug analysis is not easily automated and adds processing time and effort to the clinical laboratory analysis.

The last common reason for TDM of AEMs is to assess compliance (adherence) to therapy such as in a patient who shows a lack of clinical response or the loss of efficacy in a therapy that was previously effective (Patsalos et al., 2008). Epilepsy therapy can occur over long periods of time even in the absence of seizures. Similar to other medications that may be taken chronically (e.g., anti-depressants, anti-hypertensives), patients may skip doses or stop taking the medication due to side effects, medication expense, or other factors.

3. Reference ranges for AEMs

Reference ranges for AEMs are challenging to establish. Ideally, TDM would guide physicians towards serum/plasma concentrations that optimally control seizures while avoiding or minimizing adverse effects. The ‘reference range’ of an AEM can be defined by a lower limit below which therapeutic effect is unlikely and an upper limit above which toxicity is likely (Patsalos et al., 2008). Reference ranges may vary with different types of seizures, or when AEMs are used for other purposes such as treatment of bipolar disorder or chronic pain. A special challenge occurs with defining reference ranges for the newer generation AEMs, which were generally studied in clinical trials as adjunctive therapy and not as monotherapy. Perucca has advocated the concept of ‘individual therapeutic concentrations’ (Perucca, 2000) wherein a patient is treated until good seizure control is achieved. The serum/plasma concentration at which good seizure control occurs serves as the patient’s individual therapeutic concentration that can be used as the target concentration to maintain during chronic therapy. TDM for AEMs is especially important when there are factors that can alter AEM pharmacokinetics, e.g., pregnancy, impaired kidney or liver function, or concomitant therapy with hepatic enzyme-inducing or – inhibiting drugs.

With the background and theory on TDM above, each of the AEMs will be discussed in turn with regard to TDM. Table 1 summarizes the pharmacokinetic properties of the AEMs, while Table 2 presents a summary of the justifications of TDM for the AEMs. References for reference ranges used in Table 1 are as follows: carbamazepine, clonazepam, phenobarbital, phenytoin, primodone, valproic acid (Hardman et al., 1996), felbamate (Faught et al., 1993; Sachdeo et al., 1992), gabapentin (Lindberger et al., 2003), lacosamide (Kellinghaus, 2009), lamotrigine (Bartoli et al., 1997), levetiracetam (Leppik et
al., 2002), oxcarbazepine (10-hydroxycarbazepine metabolite) (Friis et al., 1993), pregabalin (Patsalos et al., 2008), stiripentol (Farwell et al., 1993), tiagabine (Uthman et al., 1998), topiramate (Johannessen et al., 2003), vigabatrin (Patsalos, 1999), and zonisamide (Glauser & Pippenger, 2000; Mimaki, 1998).

4. TDM of the first generation AEMs

The first generation AEMs are commonly managed by TDM, in large part due to complex and variable pharmacokinetics. In general, the first generation agents have narrow therapeutic indices, with high plasma concentrations frequently associated with central nervous system (CNS) and other adverse effects. Several of the first generation AEMs, especially phenytoin, have high degrees of binding to plasma proteins; consequently, free drug concentrations in plasma can be clinically useful in some patients (Dasgupta, 2007). Three of the first generation AEMs (carbamazepine, phenobarbital, and phenytoin) are strong inducers of liver drug-metabolizing enzymes, particularly of CYP3A4. CYP3A4 has very wide substrate specificity including for cyclosporine, tacrolimus, and theophylline, as well as endogenous compounds such as estradiol and vitamin D (Luo et al., 2004). The accelerated metabolism of ethinyl estradiol that can occur during therapy with CYP3A4 inducers can lead to ineffectiveness of estrogen-containing oral contraceptives and unintended pregnancy (Crawford, 2002). Chronic therapy with carbamazepine, phenobarbital, and phenytoin is also well-known to have the potential risk of osteomalacia secondary to vitamin D deficiency (Zhou et al., 2006).

4.1 Carbamazepine

Carbamazepine has complicated pharmacokinetics that favors use of TDM (Neels et al., 2004; Warner et al., 1998). Carbamazepine is generally well-absorbed following oral administration; however, absorption may be delayed considerably by large doses. The metabolism of carbamazepine is quite complex, with the main metabolite being carbamazepine 10,11-epoxide, a compound that shows similar anticonvulsant activity to carbamazepine. In chronic therapy, concentrations of the epoxide metabolite may reach plasma concentrations 50% that of the parent drug. As described above, carbamazepine is a strong inducer of liver drug-metabolizing enzymes, including the CYP3A4 enzyme that metabolizes carbamazepine itself. Thus, carbamazepine represents an example of a drug that shows ‘autoinduction’, namely that the metabolism of carbamazepine increases as the drug is used chronically (Pitlick & Levy, 1977). Auto-induction is usually complete by 2-3 weeks, although it can take longer in some individuals.

Like other first generation AEMs, neurological side effects are common with high doses of carbamazepine, particularly when the plasma concentration exceeds 9 mg/L. Carbamazepine can also produce rare idiosyncratic adverse effects including severe dermatologic reactions such as Steven-Johnson Syndrome or toxic epidermal necrolysis. There is an association with severe skin reactions during carbamazepine therapy with the human leukocyte antigen (HLA) allele HLA-B*1502 which is common in patients with South Asian ancestry, particularly India (Alfirevic et al., 2006; Lonjou et al., 2006). Pharmacogenetic testing for this allele may be useful in patients of South Asian descent who are being considered for therapy with carbamazepine.
| Drug                   | Oral bioavailability | Serum protein binding | Time to peak conc. (hrs) | Serum half-life (hrs) | Reference range in serum (mg/L) |
|------------------------|----------------------|-----------------------|--------------------------|----------------------|--------------------------------|
| Carbamazepine          | >70                  | 75                    | 4-8                      | 10-20                | 4-10                           |
| Clonazepam             | >95                  | 85                    | 1-2                      | 20-26                | 0.005-0.07                     |
| Eslicarbazepine acetate| ≥80                  | 30                    | 1-4                      | 20-24                | Not established                 |
| Ethosuximide           | >90                  | 0                     | 2-4                      | 30-50                | 40-100                          |
| Felbamate              | >90                  | 25                    | 2-6                      | 16-22a               | 30-60                           |
| Gabapentin             | <60                  | 0                     | 2-3                      | 5-9                  | 2-20                            |
| Lacosamide             | ≥95                  | 15                    | 0.5-4                    | 12-13                | 5-10                            |
| Lamotrigine            | ≥95                  | 55                    | 1-3                      | 15-35a,b             | 3-14                            |
| Levetiracetam          | ≥95                  | 0                     | 1                       | 6-8                  | 12-46                           |
| Oxcarbazepine          | 90                   | 40                    | 3-6                      | 8-15a                | 3-35                            |
| Phenobarbital          | >95                  | 50                    | 4-12                     | 90-110               | 10-25                           |
| Phenytoin              | 90                   | >95                   | 4-12                     | 6-24                 | 10-20                           |
| Primidone              | >90                  | 20                    | 2-4                      | 10-20                | 8-12                            |
| Pregabalin             | ≥90                  | 0                     | 1-2                      | 5-7                  | 2.8-8.3                         |
| Rufinamide             | 85                   | 30                    | 5-6                      | 8-12a                | Not established                 |
| Stiripentol            | ≥90                  | 99                    | 1-2                      | Variable             | 4-22                            |
| Tiagabine              | ≥90                  | 96                    | 1-2                      | 5-9a                 | 0.02-0.2                        |
| Topiramate             | ≥80                  | 15                    | 2-4                      | 20-30                | 5-20                            |
| Valproic acid          | >95                  | >90                   | 1-4                      | 11-17                | 30-100                          |
| Vigabatrin             | ≥60                  | 0                     | 1-2                      | 5-8                  | 0.8-36                          |
| Zonisamide             | ≥65                  | 50                    | 2-5                      | 50-70a               | 10-40                           |

a Serum half-life significant decreased with concomitant therapy with liver enzyme inducers (rifampin, carbamazepine, phenobarbital, phenytoin, St. John’s wort)
b Serum half-life significantly increased with concomitant therapy with valproic acid.

Table 1. Pharmacokinetic Parameters and Reference Ranges for the AEMs

TDM is frequently used in carbamazepine therapy due to the challenging pharmacokinetics. Monitoring of carbamazepine is usually achieved by a variety of marketed immunoassays that have high specificity for the parent drug and limited cross-reactivity with the metabolites (Warner et al., 1998). TDM sometimes also includes monitoring of the epoxide metabolite, which can contribute a substantial amount of the therapeutic effect. One challenge of monitoring the epoxide metabolite is that commercial immunoassays specific for this metabolite are not available, and thus a technology such as high-performance liquid chromatography (HPLC) is generally needed, which usually means the analysis is performed at reference laboratories.

4.2 Clonazepam

Clonazepam is a benzodiazepine used in treatment of epilepsy, as well as in a variety of other conditions such as anxiety or panic disorders, restless legs syndrome, and mania (Riss et al., 2008). Other benzodiazepines such as diazepam and lorazepam are used commonly for acute management of seizures but not as often for long-term management. In general,
benzodiazepines are limited by tolerance during chronic therapy. Clonazepam is extensively metabolized, with less than 1% of the administered dose recovered as parent drug. The main metabolite is 7-aminoclonazepam, which is therapeutically inactive.

TDM has a relatively limited role in clonazepam therapy (Warner et al., 1998). Plasma concentrations do not correlate all that tightly with therapeutic effect, with a wide range of concentrations (5 to 70 ng/mL) associated with effective management of seizures. Higher plasma concentrations are associated with increased frequency of CNS side effects such as drowsiness or lethargy. Other than to establish an individual therapeutic concentration or to assess compliance with therapy or evaluate possible toxic effects, monitoring of clonazepam is generally of limited value.

4.3 Ethosuximide
Ethosuximide has excellent bioavailability and is not bound to any appreciable degree to plasma proteins (Brodie & Dichter, 1997; Perucca, 1996). Approximately 25% of the ingested drug is excreted unchanged. The remainder of the excretion is mostly to a hydroxyethyl metabolite, which is inactive with respect to anticonvulsant effect. Ethosuximide has a fairly wide therapeutic range with effective antiseizure activity commonly occurring with plasma concentrations of 40-100 mg/L. CNS and gastrointestinal side effects are more common with plasma concentrations exceeding 100 mg/L. TDM is commonly applied to ethosuximide therapy, although not as commonly as first generation AEMs such as carbamazepine, phenobarbital, and phenytoin that have more challenging pharmacokinetics (Warner et al., 1998).

4.4 Phenobarbital and primidone
Phenobarbital and primidone are structurally related compounds used in the management of epilepsy (Brodie & Dichter, 1997; Perucca, 1996). Primidone is converted to phenobarbital and phenylethylmalonamide (PEMA) by metabolism, with both metabolites contributing significant anticonvulsant activity. Phenobarbital and primidone show excellent absorption following oral dosing, although absorption of phenobarbital can be slow, especially with high doses. One of the striking pharmacokinetic features of phenobarbital is a long half-life, up to 100 hrs or more in adults and somewhat shorter (~80 hrs) in neonates.

TDM is commonly used for both phenobarbital and primidone (Warner et al., 1998). Plasma concentrations of 10-35 mg/L are generally recommended for phenobarbital management of seizures. Above 35 mg/L, CNS-related adverse effects are more frequent. TDM of primidone is complicated to interpret due to the formation of two active metabolites (phenobarbital and PEMA). Monitoring of primidone therapy often involves measurement of both primidone and phenobarbital plasma concentrations, both of which can be done with commercial immunoassays.

4.5 Phenytoin
Phenytoin is likely the AEM for which TDM is applied most frequently (Warner et al., 1998). Phenytoin has very challenging pharmacokinetic properties. While absorption of the drug following ingestion is high, time to peak concentrations are variable (3-12 hrs) depending on dosage and intake relative to meals. Phenytoin is extensively bound to plasma proteins, and clinically significant increased free fractions are observed in neonates, patients with
hypoalbuminemia, and in patients with uremia due to renal failure (Dasgupta, 2007). Phenytoin has complex metabolism, with saturation of hepatic enzymes at therapeutic plasma concentrations, leading to zero-order (saturation) elimination kinetics. Two of the enzymes that catalyze the metabolism of phenytoin, CYP2C9 and CYP2C19, show pharmacogenetic variation, with individuals with lower catalytic activity (poor metabolizers) at risk for developing supra-therapeutic concentrations (Ninomiya et al., 2000). Phenytoin’s unusual pharmacokinetic profile makes maintaining patients at therapeutic plasma concentrations a tricky and time-consuming goal that depends on recurrent TDM. Unfortunately, TDM cannot currently predict some of the annoying and occasionally serious adverse effects of phenytoin such as dermatologic reactions, hirsutism, and gingival overgrowth (Perucca, 1996). The latter two reactions occur unpredictably with chronic phenytoin therapy.

4.6 Valproic acid

Valproic acid has overall excellent bioavailability, although absorption can be delayed considerably with higher doses or when the drug is ingested with meals (Brodie & Dichter, 1997; Perucca, 1996). Valproic acid is approximately 90% bound to plasma proteins. Although measurement of free valproic acid concentrations in plasma is usually not needed for TDM, patients with hypoalbuminemia are at higher risk of having supra-therapeutic free concentrations. Valproic acid is extensively metabolized, with some of the metabolites having some anticonvulsant activity. Valproic acid is an inhibitor of multiple CYP enzymes and as such can cause drug-drug interactions, including with other AEMs such as carbamazepine, felbamate, lamotrigine, phenobarbital, phenytoin, and stiripentol (Besag & Berry, 2006). Valproic acid can cause hepatitis (with elevations of enzymes such as alanine aminotransferase), in some cases manifesting as fulminant liver failure. Consequently, many physicians periodically monitor hepatic enzymes and also instruct patients to seek medical attention with any signs or symptoms of liver damage such as abdominal pain or jaundice.

Valproic acid has a therapeutic range of 30-100 mg/L. CNS side effects are more common when plasma concentrations exceed 100 mg/L although some patients may have plasma concentrations of 150 mg/L or higher without adverse effects. Given the wide range of plasma concentrations associated with successful therapy, TDM can be especially valuable in valproic acid therapy in establishing an individual therapeutic concentration (Warner et al., 1998).

5. TDM of the new generation AEMs

5.1 Eslicarbazepine

Eslicarbazepine acetate [(S)-licarbazepine acetate] is a pro-drug that is rapidly and nearly completely metabolized to eslicarbazepine by liver esterases (Falcao et al., 2007; Maia et al., 2005). TDM focuses on eslicarbazepine and not on the minor metabolites oxcarbazepine (also used as an AEM) and (R)-licarbazepine. Unlike carbamazepine, eslicarbazepine does not exhibit auto-induction in metabolism, has low (~30%) binding to serum proteins, and overall has a low potential for drug-drug interactions (Almeida et al., 2010; Bialer et al., 2009). Eslicarbazepine has an elimination half-life of 20-24 hr during chronic administration
Mild to moderate hepatic failure has minimal impact on the pharmacokinetics of eslicarbazepine (Almeida et al., 2008). The main route of elimination of eslicarbazepine and other minor metabolites of eslicarbazepine acetate is via the kidneys, with moderate or severe renal failure significantly reducing the clearance of eslicarbazepine. Hemodialysis effectively removes eslicarbazepine and other metabolites of eslicarbazepine acetate (Maia et al., 2008).

Overall, TDM has a minor role in the therapeutic use of eslicarbazepine given the relatively predictable pharmacokinetics of the drug. TDM for eslicarbazepine may be useful in patients with renal failure. An enantioselective high-performance liquid chromatography-ultraviolet (HPLC-UV) method has been developed for the specific monitoring of eslicarbazepine and its metabolites (Alves et al., 2007).

5.2 Felbamate

Felbamate is approved in the United States for the treatment of partial seizures in adults and for Lennox-Gastaut Syndrome, a type of childhood epilepsy that is often refractory to AEM therapy (Bourgeois, 1997; Pellock et al., 2006). The use of felbamate has been limited due to the risks of aplastic anemia and severe liver failure, which led to revised labeling and restricted use of felbamate (Pellock et al., 2006). It is suspected that one or more metabolites of felbamate mediate the rare but serious adverse effects (Shumaker et al., 1990). Approximately 50% of the parent drug is metabolized by the liver to inactive metabolites (Shumaker et al., 1990; Thompson et al., 1999). Inducers of hepatic metabolism increase the metabolism of felbamate (Sachdeo et al., 1993; Wagner et al., 1991), while valproic acid inhibits the metabolism (Ward et al., 1991).

A clear reference range has not been established for felbamate, but seizure control usually occurs with serum/plasma concentrations of 30-60 mg/L (Faught et al., 1993; Sachdeo et al., 1992). Children clear felbamate approximately 20-65% faster than adults (Perucca, 2006). TDM may be helpful in felbamate therapy given the variable metabolism across individuals. Close monitoring of liver function and blood counts are advised during felbamate therapy, with the goal to discontinue therapy if any signs of bone marrow or liver damage appear.

5.3 Gabapentin

Gabapentin was originally approved in the United States for the treatment in epilepsy but is currently used more often for the management of chronic pain (LaRoche & Helmers, 2004b; McLean, 1995). Gabapentin is rapidly absorbed by the L-amino acid transport system (Vollmer et al., 1988), and a study published in 1998 showed possible saturability of this system, with a decrease in bioavailability at doses of 4,800 mg/day of gabapentin as compared to lower doses (Gidal et al., 1998). However, a later study showed linear absorption up to 4,800 mg/day (Berry et al., 2003). Gabapentin does not distribute much into saliva, precluding the utility of salivary gabapentin concentrations for TDM (Berry et al., 2003). Gabapentin is not metabolized to any appreciable degree and has low binding to serum proteins (Vollmer et al., 1988). The bulk of excretion is via the kidneys, with the half-life increasing in patients with renal failure. Hemodialysis effectively clears gabapentin (Hung et al., 2008; Wong et al., 1995).

Gabapentin does not have a clear reference range (Armijo et al., 2004), although effective control of seizures generally requires concentrations of 2 mg/L or higher (Sivenius et al.,
Therapeutic Drug Monitoring of Antiepileptic Medications

An approximate reference range of 2-20 mg/L for management of seizure disorders has been proposed (Lindberger et al., 2003). TDM is not usually necessary for gabapentin therapy other than to adjust dosing in patients with impaired kidney function or to assess adherence to therapy (Patsalos et al., 2008).

5.4 Lacosamide
Lacosamide is a novel functionalized amino acid that enhances inactivation of voltage-gated sodium channels (Curia et al., 2009; Perucca et al., 2008b). Lacosamide was approved in Europe in 2008 for partial-onset seizures in patients 16 years and older (Chung et al., 2010). Lacosamide has high bioavailability (~100%) and serum protein binding (Ben-Menachem et al., 2007; Luszczki, 2009). Approximately 60% of the parent drug is metabolized, mainly by CYP2C19 to an inactive metabolite. The remaining 40% is excreted unchanged by the kidneys. The low plasma protein binding of lacosamide suggests that the drug should be cleared effectively by dialysis, although data on this has not yet been published (Lacerda et al., 2006). The half-life of lacosamide is approximately 12 hours. Drug-drug interactions involving lacosamide appear to be uncommon (Beydoun et al., 2009; Johannesssen Landmark & Patsalos, 2010). The predictable pharmacokinetics of lacosamide, along with lack of clinically significant drug-drug interactions, suggests a limited role for TDM in managing lacosamide pharmacotherapy. Consequently, TDM of lacosamide has limited benefit except in patients with severe liver and/or kidney failure, or to assess compliance with therapy (Cross & Curran, 2009; Thomas et al., 2006).

5.5 Lamotrigine
Lamotrigine has been approved by the United States Food and Drug Administration (FDA) for treatment of partial seizures and bipolar disorder (Neels et al., 2004; Patsalos et al., 2008). The major adverse effect of lamotrigine is dermatologic reaction, including severe Stevens-Johnson and toxic epidermal necrolysis syndromes (Knowles et al., 1999). Harm from skin reactions have been reduced by the clinical practice of cautiously escalating dose and promptly ceasing therapy if potential skin reactions appear. One of the major advantages of lamotrigine is a solid safety record in pregnancy, which contrasts with the teratogenic effects of first-generation AEMs such as carbamazepine, phenytoin, and valproic acid (Sabers & Tomson, 2009; Tomson & Battino, 2007).

Lamotrigine is quickly and completely absorbed from the gastrointestinal tract and is only ~50% bound to serum proteins. Lamotrigine distributes into saliva, and salivary lamotrigine concentrations correlate well with those in serum, allowing for saliva to serve as an alternative sample for TDM (Ryan et al., 2003; Tsiroupolos et al., 2000). Lamotrigine is extensively metabolized, principally by glucuronidation to form an inactive metabolite (Hussein & Posner, 1997; Rambeck & Wolf, 1993). Similar to carbamazepine, lamotrigine shows the phenomenon of autoinduction during chronic therapy. Autoinduction is usually complete within two weeks, with a ~20% reduction in steady-state serum/plasma concentrations if the dose is not increased (Hussein & Posner, 1997). Classic liver enzyme inducers significantly increase the metabolism of lamotrigine, reducing the serum half-life from 15-35 hr to approximatley 8-20 hr (Hussein & Posner, 1997; Rambeck & Wolf, 1993). Ethinyl estradiol-containing oral contraceptives also significantly increase the clearance of lamotrigine (Reimers et al., 2007; Sabers et al., 2001; Sabers et al., 2003). Valproic acid inhibits the metabolism of lamotrigine and can increase the serum half-life to up to 60 hr (Biton, 1991).
Novel Treatment of Epilepsy

2006; Ramsay et al., 1991). Severe renal failure increases the serum half-life to ~50 hr in patients. Hemodialysis effectively clears lamotrigine (Fillastre et al., 1993). The clearance of lamotrigine is higher in children (Bartoli et al., 1997; Perucca, 2006) and much higher (~300%) in pregnancy (Perucca, 2006). A reference range of 3-14 mg/L has been advocated for refractory epilepsy therapy (Morris et al., 1998). The risk of toxicity increases significantly when serum/plasma concentrations exceed 15 mg/L (Besag et al., 1998; Morris et al., 1998).

TDM of lamotrigine is useful for several main reasons. First, the drug shows significant interindividual variation in liver metabolism, which can be affected by concomitant medications. Second, the clearance of lamotrigine varies across development and particularly increases during pregnancy (Pennell et al., 2008). Lastly, there is a fairly clear concentration (> 15 mg/L) above which adverse effects become more frequent (Bartoli et al., 1997; Biton, 2006; Rambeck & Wolf, 1993).

5.6 Levetiracetam

Levetiracetam is a novel anticonvulsant structurally unrelated to other AEMs (Klitgaard, 2001; Leppik, 2001). Following oral administration, levetiracetam is rapidly and nearly completely absorbed, with the rate of oral absorption slowed by co-ingestion with food (Fay et al., 2005; Patsalos, 2000). Levetiracetam distribute extensively into saliva, with salivary concentrations usually being slightly higher than serum concentrations in patients receiving chronic therapy (Lins et al., 2007). Salivary and serum levetiracetam concentrations correlate well with one another, making saliva an alternative sample to perform TDM (Grim et al., 2003; Mecarelli et al., 2007).

Levetiracetam shows low binding to serum proteins and has linear pharmacokinetics. Nearly 100% of the absorbed drug is ultimately excreted by the kidneys (Patsalos, 2004), with approximately two-thirds as the parent drug and one-thirds as a metabolite that is formed by hydrolysis in the blood (Patsalos et al., 2006). There is very little, if any, metabolism of levetiracetam by the liver and, consequently low probability of significant drug-drug interactions (Johannessen Landmark and Patsalos, 2010). Given the low plasma protein binding, levetiracetam is likely efficiently cleared by hemodialysis (Lacerda et al., 2006). The serum half-life of levetiracetam is shorter in adult (6-8 hr) compared to neonates (16-18 hr) (Patsalos et al., 2008). Clearance of levetiracetam increases significantly in pregnancy, with an approximately 60% decrease in serum concentrations (Tomson and Battino, 2007).

A reference range of 12-46 mg/L has been proposed based on a study of 470 patients in a specialty epilepsy clinic (Leppik et al., 2002). Other than to assess compliance or investigate potential toxicity, the main value of TDM for levetiracetam is in adjusting dosage for renal insufficiency (Patsalos, 2000, 2004; Patsalos et al., 2008; Radtke, 2001). In collecting samples for drug monitoring, serum or plasma should be separated from whole blood rapidly, as in vitro hydrolysis of levetiracetam can occur in the blood tube and thus lead to artifactually low concentrations (Patsalos et al., 2006).

5.7 Oxcarbazepine

Oxcarbazepine has a chemical structure related to carbamazepine but causes less induction of liver enzymes. Oxcarbazepine is rapidly and completely absorbed and
Therapeutic Drug Monitoring of Antiepileptic Medications

10-Hydroxycarbazepine is further metabolized, primarily by glucuronidation. The clearance of 10-hydroxycarbazepine is reduced in renal insufficiency (Rouan et al., 1994) and in the elderly (Perucca, 2006). The clearance of 10-hydroxycarbazepine is increased in pregnancy (Christensen et al., 2006; Mazzucchelli et al., 2006) and in patients taking liver enzyme-inducing drugs (May et al., 2003). Children require higher doses of oxcarbazepine per body weight than adults (Battino et al., 1995). 10-Hydroxycarbazepine and oxcarbazepine have similar potencies for anticonvulsant activity; however, 10-hydroxycarbazepine generally accumulates to higher concentrations in serum and thus accounts for the majority of the antiseizure activity (Lloyd et al., 1994).

Consequently, TDM for oxcarbazepine generally focuses on measurement of serum/plasma concentrations of the monohydroxy metabolite (Patsalos et al., 2008). Although 10-hydroxycarbazepine distributes into saliva, there are dose-dependent variations in the correlation between 10-hydroxycarbazepine saliva and serum concentrations that limit the utility of saliva as an alternative specimen for TDM of oxcarbazepine (Cardot et al., 1995; Kristensen et al., 1983; Miles et al., 2004). In clinical research studies, a wide range of 10-hydroxycarbazepine serum concentrations (3-35 mg/L) were observed to be clinically effective in seizure treatment (Friis et al., 1993), with toxic side effects being more common at serum/plasma concentrations of 35 mg/L or higher (Striano et al., 2006). TDM for oxcarbazepine is justified when changes are expected that might alter 10-hydroxycarbazepine clearance including pregnancy, concomitant use of liver enzyme-inducing drugs, or renal insufficiency.

5.8 Pregabalin

Pregabalin was originally designed to be a more potent analog of gabapentin (Selak, 2001) and shares many clinical similarities to gabapentin, including widespread use to manage conditions other than epilepsy such as neuropathic pain and fibromyalgia (Acharya et al., 2005; LaRoche & Helmers, 2004a). Pregabalin has very advantageous pharmacokinetics including high bioavailability, low binding to plasma proteins, minimal metabolism, and no significant drug-drug interactions (Busch et al., 1998). The majority of the absorbed dose (~98%) is excreted unchanged in the urine. Clearance of pregabalin approximates glomerular filtration rate (Corrigan et al., 2001), and dosing of pregabalin may need adjustment in patients with impaired renal function (Randinitis et al., 2003). Pregabalin is effectively cleared by hemodialysis (Yoo et al., 2009). An approximate reference range of 2.8-8.3 mg/L has been proposed for the use of pregabalin in managing seizures (Patsalos et al., 2008). The favorable pharmacokinetics of pregabalin generally obviates the need for TDM, other than to adjust dosing during renal failure or to assess compliance. If monitoring is performed, the short half-life of pregabalin (4.6-5.8 hr) (Bockbrader et al., 2000) necessitates that care must be taken in the timing of blood draws for TDM.

5.9 Rufinamide

Rufinamide is a novel anticonvulsant approved for use in Europe in January 2007 and in the United States in December 2008 for Lennox-Gastaut syndrome (Hakimian et al., 2007; Heaney & Walker, 2007; Wheless & Vazquez, 2010; Wisniewski, 2010). Rufinamide is well-
absorbed (80-90%) following oral administration (Perucca et al., 2008a). The peak exposure to rufinamide may increase significantly when taken with food as compared to an empty stomach. Consequently, patients are often counseled to take rufinamide in the same temporal relation to meals. Rufinamide is extensively metabolized, primarily by carboxyesterases, with only trace amounts of the parent drug excreted in feces or urine. The primary metabolite is inactive and mainly excreted by the kidneys. Hepatic enzyme inducers such as carbamazepine and rifampin increase the excretion of rufinamide (Perucca et al., 2008a). Impaired renal function has minimal effect on clearance of rufinamide; however, increased doses of rufinamide are often needed in patients receiving hemodialysis due to removal of the drug by the dialysis procedure. Although reference ranges for rufinamide have not been well-defined yet, serum/plasma concentrations generally correlate with seizure control, allowing for determination of an individual therapeutic concentration that can be monitored over the course of chronic therapy (Luszczki, 2009; Perucca et al., 2008a; Wheless & Vazquez, 2010) TDM for rufinamide can be especially helpful in patients receiving hemodialysis or who are also taking liver enzyme inducers.

5.10 Stiripentol
Stiripentol is an AEM that was originally approved in Europe in 2001 but is currently infrequently used. Stiripentol is rapidly absorbed following oral administration but has overall low bioavailability, in large part due to extensive first-pass metabolism by the liver. The hepatic metabolism of stiripentol is very complex, with at least 5 different metabolic pathways generating over a dozen metabolites. The dosing of stiripentol is further complicated by zero-order (saturation) elimination kinetics, with a marked decrease in clearance with increased dosage (Levy et al., 1983). Stiripentol is also highly (>99%) protein bound and prone to drug interactions that can alter the free fraction (Lacerda et al., 2006). A well-defined reference range for stiripentol has not been established, although one study showed that serum concentrations of 4-22 mg/L correlate with control of absence seizures in children (Farwell et al., 1993). The complex pharmacokinetics of stiripentol (extensive hepatic metabolism, high binding to plasma protein, and saturation kinetics) resemble that of phenytoin (Luszczki, 2009). Measurement of the free drug fraction of stiripentol may be clinically useful; however, methods to measure free fractions have not yet been reported. When used in combination AEM therapies, stiripentol may cause drug-drug interactions by inhibiting the metabolism of carbamazepine, clobazam, phenobarbital, phenytoin, and valproic (Levy et al., 1984; Tran et al., 1997; Tran et al., 1996).

5.11 Tiagabine
Tiagabine is currently approved in the United States and Europe but is used infrequently due to a propensity to cause non-convulsive status epilepticus (Eckardt & Steinhoff, 1998; Kellinghaus et al., 2002; Schapel & Chadwick, 1996). Tiagabine is rapidly absorbed with high bioavailability but, unlike many of the other newer AEMs, is highly bound to proteins (>96%) (Gustavson & Mengel, 1995). Co-therapy with valproic acid can increase the free concentrations of tiagabine by displacing tiagabine from serum protein binding sites (Patsalos et al., 2002). The hepatic metabolism of tiagabine is complex and extensive
with less than 1% of the absorbed parent drug excreted unchanged (Gustavson & Mengel, 1995). The metabolism of tiagabine can be altered by concomitant therapy with liver enzyme inhibitors or inducers. The serum half-life is typically 5-9 hr for patients on tiagabine monotherapy. The half-life is reduced to 2-4 hr in patients receiving enzyme inducers (So et al., 1995). The serum half-life increases to 12-16 hr in severe liver failure (Lau et al., 1997). Children have higher clearance than adults (Gustavson et al., 1997). Renal dysfunction does not significantly impact the pharmacokinetics of tiagabine (Cato et al., 1998).

The inter-individual variation in hepatic metabolism makes tiagabine a candidate for TDM. Further, the extensive binding of tiagabine to plasma proteins further suggests that measurement of free drug concentrations may be clinically useful (Dasgupta, 2007). However, a clear relationship between tiagabine serum/plasma concentration and therapeutic efficacy has not yet been established, with a broad reference range of 20-200 ng/mL proposed (Patsalos et al., 2008; Uthman et al., 1998). For measurement of free drug concentrations, analytical sensitivity is an issue, with some assays having insufficiently low limits of sensitivity to measure clinically relevant free drug concentrations (Williams et al., 2003). Consequently, such analysis is only performed at specialized reference laboratories.

5.12 Topiramate
Topiramate has approval for treatment of epilepsy of children and adults, and also for the treatment of migraine headaches (LaRoche & Helmers, 2004a). Topiramate has high bioavailability (~80%) and low binding to serum proteins (Easterling et al., 1988). Salivary topiramate concentrations correlate well with those in serum (with salivary concentrations being roughly 0.9 that in serum), which makes saliva an alternative specimen type for TDM (Jones et al., 2005; Miles et al., 2003). Approximately 50% of the absorbed dose is metabolized by the liver. Hepatic enzyme inducers can decrease the serum half-life of topiramate from 20-30 hr to approximately 12 hr (Britzi et al., 2005; Sachdeo et al., 1996). Children generally eliminate topiramate faster than adults (Perucca, 2006; Rosenfeld et al., 1999). A reference range of 5-20 mg/L has been proposed for topiramate for epilepsy therapy (Johannessen et al., 2003). TDM of topiramate is most useful due to variability in metabolism.

5.13 Vigabatrin
Vigabatrin is an irreversible inhibitor of GABA transaminase, an enzyme that catalyzes the elimination of GABA (Rey et al., 1992; Schechter, 1989). Vigabatrin has high bioavailability (60-80%), low binding to serum proteins and is primarily excreted unchanged in the urine (Durham et al., 1993; Rey et al., 1992). Dose reductions of vigabatrin are generally needed in patients with renal failure (Rey et al., 1992). Clearance of vigabatrin increased during hemodialysis (Jacqz-Aigrain et al., 1997). The irreversible action of vigabatrin on its molecular target is likely the reason a wide range of serum/plasma concentrations (0.8-36 mg/L) of vigabatrin are associated with successful treatment with vigabatrin. Other than to assess compliance or possible drug overdose, there is little value in monitoring vigabatrin plasma/serum concentrations (Patsalos, 1999).
| Drug              | Need for TDM | Factors Favoring TDM                                                                 | Limitations of TDM                                                                 |
|-------------------|--------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Carbamazepine     | Frequent     | Auto-induction of metabolism; drug-drug interactions; high serum protein binding    | Free drug concentrations needed for some patients                                   |
| Clonazepam        | Uncommon     | Distinguish tolerance from inadequate dosing                                        | Wide reference range; low toxicity incidence                                       |
| Eslicarbazepine   | Intermediate | Decreased clearance with chronic dosing and liver failure                           | Generally predictable pharmacokinetics                                              |
| Ethosuximide      | Intermediate | Complex metabolism                                                                  | Wide reference range; variable toxicity range                                      |
| Felbamate         | Intermediate | Variable metabolism, potential for severe toxicity                                   | Uncertain reference range                                                          |
| Gabapentin        | Uncommon     | Decreased clearance with renal failure                                              | Wide reference range; low toxicity incidence                                       |
| Lacosamide        | Uncommon     |                                                                                     | Predictable dosing                                                                 |
| Lamotrigine       | Frequent     | Variable metabolism; significant drug-drug interactions                              |                                                                                     |
| Levetiracetam     | Intermediate | Decreased clearance with renal failure                                              | Wide reference range; low toxicity incidence                                       |
| Oxcarbazepine     | Intermediate to Frequent | Variable metabolism, well-defined toxic range                      |                                                                                     |
| Phenobarbital     | Frequent     | Drug-drug interactions, long half-life                                              | Tolerance to drug can complicate TDM                                               |
| Phenytoin         | Frequent     | Variable absorption; high serum protein binding; drug-drug interactions; zero-order kinetics | Free drug concentrations needed in some populations                                      |
| Primidone         | Intermediate | Long half-life of metabolites, potential for toxicity                                | Need to monitor phenobarbital as well                                              |
| Pregabalin        | Uncommon     | Decreased clearance with renal failure                                              | Wide reference range; low toxicity incidence                                       |
| Rufinamide        | Intermediate to Frequent | Variable absorption; drug-drug interactions; decreased clearance with renal failure | Uncertain reference range                                                          |
| Stiripentol       | Frequent     | Extensive first-pass metabolism, high serum protein binding, zero-order kinetics    |                                                                                     |
| Tiagabine         | Intermediate | High serum protein binding                                                          | Uncertain reference range                                                          |
| Topiramate        | Intermediate | Variable metabolism                                                                | Limited correlation of plasma concentration and efficacy                          |
| Valproic acid     | Frequent     | Well-established therapeutic range                                                  |                                                                                     |
| Vigabatrin        | Uncommon     |                                                                                     | Irreversible action                                                                 |
| Zonisamide        | Frequent     | Variable metabolism, well-defined toxic range                                       |                                                                                     |

Table 2. Summary of Justifications of TDM of AEMs
5.14 Zonisamide

Zonisamide is approved in the United States for adjunctive treatment of partial seizures but is also used ‘off-label’ for bipolar disorder and migraine headaches (Leppik, 1999; Mimaki, 1998). After oral administration, zonisamide is rapidly absorbed and is only approximately 50% bound to serum proteins. Zonisamide is extensively metabolized by acetylation, oxidation, and other enzymatic pathways (Buchanan et al., 1996). CYP3A4 is responsible for some of the metabolism of zonisamide. Consequently, the metabolism of zonisamide can be significantly affected by CYP inducers and inhibitors. The elimination half-life of zonisamide is approximately 50-70 hr for patients receiving zonisamide as monotherapy but decreases to 25-35 hr in patients concomitantly taking enzyme inducers such as carbamazepine or phenobarbital. On the other hand, liver enzyme inhibitors such as ketoconazole and valproic acid may prolong zonisamide half-life (Perucca & Bialer, 1996). Zonisamide is cleared effectively by hemodialysis (Ijiri et al., 2004). In general, children require higher doses by weight than adults (Perucca, 2006). A serum/plasma reference range of 10-40 mg/L has been proposed for seizure management (Glauser & Pippenger, 2000; Mimaki, 1998). Toxic side effects are uncommon at serum concentrations below 30 mg/L (Miura, 1993). The main reason to perform TDM for zonisamide is inter-individual variability in metabolism, particularly in patients concomitantly taking CYP enzyme inducers or inhibitors.

6. Conclusion

TDM has traditionally been applied to the first generation AEMs such as carbamazepine, phenobarbital, phenytoin, and valproic acid, mainly due to the challenging pharmacokinetics of this group of drugs. The newer generation AEMs generally have more favorable pharmacokinetics and fewer adverse effects. The strongest evidence for routine TDM for the new generation AEMs are for lamotrigine, oxcarbazepine (10-hydroxycarbazepine metabolite), stiripentol, tiagabine, and zonisamide. For other AEMs, TDM may have value in adjusting dosing for organ failure or to assess compliance with therapy. Future research is needed to better delineate reference ranges and to establish the benefit of TDM in clinical practice.

7. References

Acharya, NV, Pickering, RM, Wilton, LW, Shakir, SA. (2005). The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study. Journal of Clinical Pharmacology. Vol. 45, No. 4., (Apr 2005) 385-393. Print ISSN 0091-2700

al Za’abi, M, Deleu, D, Batchelor, C. (2003). Salivary free concentrations of anti-epileptic drugs: an evaluation in a routine clinical setting. Acta Neurologica Belgica. Vol. 103, No. 1. (Mar 2003) 19-23. Print ISSN 0300-9009

Alfirevic, A, Jorgensen, AL, Williamson, PR, Chadwick, DW, Park, BK, Pirmohamed, M. (2006). HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. Vol. 7, No. 6. (Sep 2006) 813-818. Print ISSN 1462-2416

Almeida, L, Falcao, A, Maia, J, Mazur, D, Gellert, M, Soares-da-Silva, P. (2005). Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. Journal of Clinical Pharmacology. Vol. 45, No. 9. (Sep 2005) 1062-1066. Print ISSN 0091-2700

www.intechopen.com
Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurologica Scandinavica. Vol. 121, No. 4. (Dec 2010) 257-264. Print ISSN 1600-0404

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. European Journal of Clinical Pharmacology. Vol. 64, No. 3. (Mar 2008) 267-273. Print ISSN 0031-6970

Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomedical Chromatography. Vol. 21, No. 11. (Nov 2007) 1127-1134. Print ISSN 0269-3879

Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis. Therapeutic Drug Monitoring. Vol. 26, No. 6. 633-637. (Dec 2004) Print ISSN 0163-4356

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessments of correlations with clinical response. Therapeutic Drug Monitoring. Vol. 19, No. 3. (Jun 1997) 252-260. Print ISSN 0163-4356

Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clinical Pharmacokinetics Vol. 29, No. 5. (Nov 1995) 341-369. Print ISSN 0312-5963

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. Vol. 48, No. 7. (Jul 2007) 1308-1317. Print ISSN 0013-9580

Oral gabapentin disposition in patients with epilepsy after a high-protein meal. Epilepsia. Vol. 38, No. 10. (Oct 1997) 1140-1142. Print ISSN 0013-9580

The absorption of gabapentin following high dose escalation. Seizure. Vol. 12, No. 1. (Jan 2003) 28-36. Print ISSN 1059-1311

Interactions between antiepileptic and antipsychotic drugs. Drug Safety. Vol. 29, No. 2. (2006) 95-118. Print ISSN 0114-5916

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction. Epilepsia. Vol. 39, No. 2. (Feb 1998) 183-187. Print ISSN 0013-9580

Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Review of Neurotherapeutics. Vol. 9, No. 1. (Jan 2009) 33-42. Print ISSN 1744-8360

The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Therapeutic Drug Monitoring. Vol. 27, No. 6. (Dec 2005) 722-726. Print ISSN 0163-4356

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Research. Vol. 83, No. 1. (Jan 2009) 1-43. Print ISSN 1872-6844
Biton, V. (2006). Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. *Expert Opinion in Drug Metabolism and Toxicology*. Vol. 2, No. 6. (Dec 2006) 1009-1018. Print ISSN 1742-5255

Bockbrader, HN, Hunt, T, Strand, J, Posvar, EL, Sedman, A. (2000). Pregabalin pharmacokinetics and safety in health volunteers: results from two phase I studies. *Neurology*. Vol. 11, Suppl 3. (2000) 412. Electronic ISSN 1526-632X

Bourgeois, BF. (1997). Felbamate. *Seminars in Pediatric Neurology*. Vol. 4, No. 1. (Mar 1997) 159-174. Print ISSN 1526-632X

Britti, MP, E., Soback, S, Levy, RH, Fattore, C, Crema, F, Gatti, G, Doose, DR, Maryanoff, BE, Bialer, M. (2005). Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. *Epilepsia*. Vol. 46, No. 3. (Mar 2005) 378-384. Print ISSN 0013-9580

Brodie, MJ, Dichter, MA. (1997). Established antiepileptic drugs. *Seizure*. Vol. 6, No. 3. (Jun 1997) 159-174. Print ISSN 1059-1311

Buchanan, R, Bockbrader, HN, Chang, T, Sedman, AJ. (1996). Single- and multiple-dose pharmacokinetics of zonisamide. *Epilepsia*. Vol. 37, No. Suppl 5. (1996) 172. Print ISSN 0013-9580

Busch, JA, Strand, JC, Posvar, EL, Bockbrader, HN, Radulovic, LL. (1998). Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. *Epilepsia*. Vol. 39, No. Suppl 6. (1998) 58. Print ISSN 0013-9580

Cardot, JM, Degen, P, Flesch, G, Menge, P, Dieterle, W. (1995). Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. *Biopharmaceutics & Drug Disposition*. Vol. 16, No. 7. (Oct 1995) 603-614. Print ISSN 0142-2782

Cato, A, 3rd, Gustavson, LE, Qian, J, El-Shourbagy, T, Kelly, EA. (1998). Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. *Epilepsia*. Vol. 39, No. 1. (Jan 1998) 43-47. Print ISSN 0013-9580

Christensen, J, Sabers, A, Sidenius, P. (2006). Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. *Neurology*. Vol. 24, No. 8. (Aug 2006) 1497-1499. Electronic ISSN 1526-632X

Chung, S, Sperling, MR, Biton, V, Krauss, G, Hebert, D, Rudd, GD, Doty, P. (2010). Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. *Epilepsia*. Vol. 51, No. 6 (June 2010) Print ISSN 0013-9580

Corrigan, BW, Poole, WF, Posvar, EL, Strand, JC, Alvey, CW, Radulovic, LL. (2001). Metabolic disposition of pregabalin in healthy volunteers. *Clinical Pharmacology and Therapeutics*. Vol. 69, Suppl. (2001) P18. Print ISSN 0009-9236

Crawford, P. (2002). Interactions between antiepileptic drugs and hormonal contraception. *CNS Drugs*. Vol. 16, No. 4. (Apr 2002) 263-272. Print ISSN 1172-7047

Cross, SA, Curran, MP. (2009). Lacosamide: in partial-onset seizures. *Drugs*. Vol. 69, No. 4. (Apr 2009) 449-459. Print ISSN 0012-6667

Curia, G, Biagini, G, Perucca, E, Avoli, M. (2009). Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. *CNS Drugs*. Vol. 23, No. 7. (Jul 2009) 555-568. Print ISSN 1172-7047

Dasgupta, A. (2007). Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. *Clinica Chimica Acta*. Vol. 377, No. 1-2. (Feb 2007) 1-13. Print ISSN 0009-8981
Durham, SL, Hoke, JF, Chen, TM. (1993). Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. *Drug Metabolism and Disposition*. Vol. 21, No. 3. (May-Jun 1993) 480-484. Print ISSN 0090-9556

Easterling, DE, Zakszewski, T, Moyer, MD, Margul, BL, Marriott, TB, Nayak, RK. (1988). Plasma pharmacokinetics of topiramate, a new anticonvulsants in humans. *Epilepsia*. Vol. 29, Suppl. (1988) Print ISSN 0013-9580

Eckardt, KM, Steinhoff, BJ. (1998). Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. *Epilepsia*. Vol. 39, No. 6. (Jun 1998) 671-674. Print ISSN 0013-9580

Falcao, A, Maia, J, Almeida, L, Mazur, D, Gellert, M, Soares-da-Silva, P. (2007). Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. *Biopharmaceutics & Drug Disposition*. Vol. 28, No. 5. (Jul 2007) 249-256. Print ISSN 0142-2782

Farwell, JR, Anderson, GD, Kerr, BM, Tor, JA, Levy, RH. (1993). Stiripentol in atypical absence seizures in children: an open trial. *Epilepsia*. Vol. 34, No. 2. (Mar-Apr 1993) 305-311. Print ISSN 0013-9580

Faught, E, Sachdeo, RC, Remler, MP, Chayasirisobhon, S, Iragui-Madoz, VJ, Ramsay, RE, Sutula, TP, Kanner, A, Harner, RN, Kuzniecky, R, Kramen, M, Rosenberg, A. (1993). Felbamate monotherapy for partial-onset seizures: an active-controlled trial. *Neurology*. Vol. 43, No. 4. (Apr 1993) 688-692. Electronic ISSN 1526-632X

Fay, MA, Sheth, RD, Gidal, BE. (2005). Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. *Clinical Therapeutics*. Vol. 27, No. 5. (May 2005) 594-598. Print ISSN 0149-2918

Fillastre, JP, Taburet, AM, Fialaire, A, Etienne, I, Bidault, R, Singlas, E. (1993). Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. *Drugs Under Experimental and Clinical Research*. Vol. 19, No. 1. (Jan 1993) 25-32. Print ISSN 0378-6501

Friis, ML, Kristensen, O, Boas, J, Dalby, M, Deth, SH, Gram, L, Mikkelsen, M, Pedersen, B, Sabers, A, Worm-Petersen, J. (1993). Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. *Acta Neurologica Scandinavica*. Vol. 87, No. 3. (Mar 1993) 224-227. Print ISSN 0001-6634

Fröscher, W, Eichelbaum, M, Gugler, R, Hildebrand, G, Penin, H. (1981). A prospective randomized trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. *Journal of Neurology*. Vol. 224, No. 3. (Mar 1981) 193-201. Print ISSN 0340-5354

Gidal, BE, DeCerce, J, Bockbrader, HN, Gonzalez, J, Kruger, S, Pitterle, ME, Rutecki, P, Ramsay, RE. (1998). Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. *Epilepsy Research*. Vol. 31, No. 2. (Jul 1998) 91-99. Print ISSN 0920-1211

Glauser, TA, Pippenger, CE. (2000). Controversies in blood-level monitoring: re-examining its role in the treatment of epilepsy. *Epilepsia*. Vol. 41, Suppl 8. (2000) S6-S15. Print ISSN 0013-9580

Grim, SA, Ryan, M, Miles, MV, Tang, PH, Strawsburg, RH, de Grauw, TJ, Fakhoury, TA, Baumann, RJ. (2003). Correlation of levetiracetam concentrations between serum and plasma. *Therapeutic Drug Monitoring*. Vol. 25, No. 1. (Dec 2003) 61-66. Print ISSN 0277-0008
Therapeutic Drug Monitoring of Antiepileptic Medications

Guo, T, Oswald, LM, Mendu, DR, Soldin, SJ. (2007). Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. *Clinica Chimica Acta*. Vol. 375, No. 1-2. (Jan 2007) 115-118. Print ISSN 0009-8891

Gustavson, LE, Boellner, SW, Granneman, GR, Qian, JX, Guenther, HJ, el-Shourbagy, T, Somerville, KW. (1997). A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. *Neurology*. Vol. 48, No. 4. (Apr 1997) 1032-1037. Electronic ISSN 1526-632X

Gustavson, LE, Mengel, HB. (1995). Pharmacokinetics of tiagabine, a g-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. *Epilepsia*. Vol. 36, No. 6. (Jun 1995) 605-611. Print ISSN 0013-9580

Hakimian, S, Cheng-Hakimian, A, Anderson, GD, Miller, JW. (2007). Rufinamide: a new anti-epileptic medication. *Expert Opinion on Pharmacotherapy*. Vol. 8, No. 12. (Aug 2007) 1931-1940. Print ISSN 1744-7666

Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. (1996). Pharmacokinetic data, In: *Goodman & Gilman’s The Pharmacological Basis of Therapeutics*, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds), pp. 1712-1792, McGraw-Hill, ISBN 0-070-026266-7, New York.

Heaney, D, Walker, MC. (2007). Rufinamide. *Drugs Today (Barcelona)*. Vol. 43, No. 7. (Jul 2007) 455-460. Print ISSN 1699-3993

Hung, TY, Seow, VK, Chong, CF, Wang, TL, Chen, CC. (2008). Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. *Emergency Medicine Journal*. Vol. 25, No. 3. (Mar 2008) 178-179. Print ISSN 1472-0213

Hussein, Z, Posner, J. (1997). Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. *British Journal of Clinical Pharmacology*. Vol. 43, No. 5. (May 1997) 457-464. Print ISSN 0306-5251

Ijiri, Y, Inoue, T, Fukuda, F, Suzuki, K, Kobayashi, T, Shibahara, N, Takenaka, H, Tanaka, K. (2004). Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. *Epilepsia*. Vol. 45, No. 8. (Aug 2004) 924-927. Print ISSN 0013-9580

Incecayir, T, Agabayoglu, I, Gucuyener, K. (2007). Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. *Arzneimittelforschung*. Vol. 57, No. 8. (Aug 2007) 517-521. Print ISSN 0004-4172

Jacqz-Aigrain, E, Guillonneau, M, Rey, E, Macher, MA, Montes, C, Chiron, C, Loirat, C. (1997). Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. *British Journal of Clinical Pharmacology*. Vol. 44, No. 2. (Aug 1997) 183-185. Print ISSN 0306-5251

Januzzi, G, Cian, P, Fattore, C, Gatti, G, Bartoli, A, Monaco, F, Perucca, E. (2000). A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. *Epilepsia*. Vol. 41, No. 2. (Feb 2000) 222-230. Print ISSN 0013-9580

Johannessen Landmark, C. (2008). Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. *CNS Drugs*. Vol. 22, No. 1. (Jan 2008) 27-47. Print ISSN 1172-7047

Johannessen Landmark, C, Patsalos, PN. (2010). Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Review of Neurotherapeutics*. Vol. 10, No. 1. (Jan 2010) 119-140. Print ISSN 1744-8360

www.intechopen.com
Johannessen, SI, Battino, D, Berry, DJ, Bialer, M, Kramer, G, Tomson, T, Patsalos, PN. (2003). Therapeutic drug monitoring of the newer antiepileptic drugs. *Therapeutic Drug Monitoring*. Vol. 25, No. 3. (Mar 2003) 347-363. Print ISSN 0277-0008

Jones, MD, Ryan, M, Miles, MV, Tang, PH, Fakhoury, TA, Degraw, TJ, Baumann, RJ. (2005). Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. *Therapeutic Drug Monitoring*. Vol. 27, No. 5. (Oct 2005) 576-579. Print 0163-4356

Kellinghaus, C. (2009). Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. *Therapeutics and Clinical Risk Management*. Vol. 5, (2009) 757-766. Print ISSN 1176-6336

Kellinghaus, C, Dziewas, R, Ludemann, P. (2002). Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. *Seizure*. Vol. 11, No. 4. (Jun 2002) 243-249. Print ISSN 1059-1311

Klitgaard, H. (2001). Levetiracetam: the preclinical profile of a new class of antiseizure drugs? *Epilepsia*. Vol. 42, Suppl 4. (2001) S13-S18. Print ISSN 0013-9580

Knowles, SR, Shapiro, LE, Shear, NH. (1999). Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. *Drug Safety*. Vol. 21, No. 6. (Dec 1999) 489-501. Print ISSN 0114-5916

Komoroski, BJ, Zhang, S, Cai, H, Hutzler, JM, Frye, R, Tracy, TS, Strom, SC, Lehmann, T, Ang, CYW, Cui, YY, Venkataramanan, R. (2004). Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. *Drug Metabolism and Disposition*. Vol. 32, No. 5. (May 2004) 512-518. Print ISSN 0090-9556

Kristensen, O, Klitgaard, NA, Jonsson, B, Sindrup, S. (1983). Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. *Acta Neurologica Scandinavica*. Vol. 68, No. 3. (Sep 1983) 145-150. Print ISSN 0001-6314

Kumagai, N, Seki, T, Yamada, T, Takuma, Y, Hirai, K. (1993). Concentrations of zonisamide in serum, free fraction, mixed saliva and cerebrospinal fluid in epileptic children treated with monotherapy. *The Japanese Journal of Psychiatry and Neurology*. Vol. 47, No. 2. (Jun 1993) 291-292. Print ISSN 0912-2036

Lacerda, G, Krummel, T, Sabourdy, C, Ryvlin, P, Hirsch, E. (2006). Optimizing therapy of seizures in patients with renal or hepatic dysfunction. *Neurology*. Vol. 67, No. 12 Suppl 4. (Dec 2006) S28-33. Electronic ISSN 1526-632X

Larkin, JG, McKee, PJ, Forrest, G, Beastall, GH, Park, BK, Lowrie, JJ, Lloyd, P, Brodie, MJ. (1991). Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. *British Journal of Clinical Pharmacology*. Vol. 31, No. 1. (Jan 1991) 65-71. Print ISSN 0306-5251

LaRoche, SM, Helmers, SL. (2004a). The new antiepileptic drugs: clinical applications. *JAMA*. Vol. 291, No. 5. (Feb 2004) 615-620. Print ISSN 0098-7484

LaRoche, SM, Helmers, SL. (2004b). The new antiepileptic drugs: scientific review. *JAMA*. Vol. 291, No. 5. (Feb 2004) 605-614. Print ISSN 0098-7484

Lau, AH, Gustavson, LE, Sperelakis, R, Lam, NP, El-Shourbagy, T, Qian, JX, Layden, T. (1997). Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. *Epilepsia*. Vol. 38, No. 4. (Apr 1997) 445-451. Print ISSN 0013-9580

Leppik, IE. (1999). Zonisamide. *Epilepsia*. Vol. 40, Suppl 5. (1999) S23-S29. Print ISSN 0013-9580

www.intechopen.com
Leppik, IE. (2001). The place of levetiracetam in the treatment of epilepsy. *Epilepsia*. Vol. 42, No. Suppl 4. (2001) S44-S45. Print ISSN 0013-9580

Leppik, IE, Rarick, JO, Walczak, TS, Tran, TA, White, JR, Guminit, RJ. (2002). Effective levetiracetam doses and serum concentrations: age effects. *Epilepsia*. Vol. 43, Suppl 7. (2002) 240. Print ISSN 0013-9580

Levy, RH, Lin, HS, Blehaut, HM, Tor, JA. (1983). Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. *Journal of Clinical Pharmacology*. Vol. 23, No. 11-12. (Nov-Dec 1983) 523-533. Print ISSN

Levy, RH, Loiseau, P, Guyot, M, Blehaut, HM, Tor, J, Moreland, TA. (1984). Stiripentol kinetics in epilepsy: nonlinearity and interactions. *Clinical Pharmacology and Therapeutics*. Vol. 36, No. 5. (Nov 1984) 661-669. Print ISSN 0009-9236

Lindberger, M, Luhr, O, Johannessen, SI, Larsson, S, Tomson, T. (2003). Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. *Therapeutic Drug Monitoring*. Vol. 25, No. 4. (Apr 2003) 457-462. Print ISSN 0277-0008

Lins, RL, Otoul, C, De Smedt, F, Coupez, R, Stockis, A. (2007). Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. *International Journal of Clinical Pharmacology and Therapeutics*. Vol. 45, No. 1. (Jan 2007) 47-54. Print ISSN 0946-1965

Liu, H, Delgado, MR. (1999). Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. *Clinical Pharmacokinetics*. Vol. 36, No. 6. (Jun 1999) 453-470. Print ISSN 0312-5963

Lloyd, P, Flesch, G, Dieterle, W. (1994). Clinical pharmacology and pharmacokinetics of oxcarbazepine. *Epilepsia*. Suppl 3 (1994) 10-13. Print ISSN 0013-9580

Lonjou, C, Thomas, L, Borot, N, Ledger, N, de Toma, C, LeLouet, H, Graf, E, Schumacher, M, Hovnanian, A, Mockenhaupt, M, Roujeau, JC. (2006). A marker for Stevens-Johnson syndrome ...: ethnicity matters. *Pharmacogenomics Journal*. Vol. 6, No. 4. (Jul-Aug 2006) 265-268. Print ISSN 1470-269X

Luo, G, Guenthner, T, Gan, L-S, Humphreys, WG. (2004). CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. *Current Drug Metabolism*. Vol. 5, No. 6. (Dec 2004) 483-505. Print ISSN 1389-2002

Luszczki, JJ. (2009). Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. *Pharmacological Reports*. Vol. 61, No. 2. (Mar-Apr 2009) 197-216. Print ISSN 1734-1140

Maia, J, Almeida, L, Falcao, A, Soares, E, Mota, F, Potgieter, MA, Potgieter, JH, Soares-da-Silva, P. (2008). Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. *International Journal of Clinical Pharmacology and Therapeutics*. Vol. 46, No. 3. (Mar 2008) 119-130. Print ISSN 0946-1965

Maia, J, Vaz-da-Silva, M, Almeida, L, Falcao, A, Silveira, P, Guimaraes, S, Graziela, P, Soares-da-Silva, P. (2005). Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). *Drugs R D*. Vol. 6, No. 4. (Apr 2005) 201-206. Print ISSN 1174-5886

Malone, SA, Eadie, MJ, Addison, RS, Wright, AW, Dickinson, RG. (2006). Monitoring salivary lamotrigine concentrations. *Journal of Clinical Neuroscience*. Vol. 13, No. 9. (Nov 2006) 902-907. Print ISSN 0967-5868

www.intechopen.com
May, TW, Korn-Merker, E, Rambeck, B. (2003). Clinical pharmacokinetics of oxcarbazepine. *Clinical Pharmacokinetics*. Vol. 42, No. 12. (Dec 2003) 1023-1042. Print ISSN 0312-5963

Mazzucchelli, I, Onat, FY, Ozkara, C, Atakli, D, Specchio, LM, Neve, AL, Gatti, G, Perucca, E. (2006). Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. *Epilepsia*. Vol. 47, No. 3. (Mar 2006) 504-509. Print ISSN 0013-9580

McLean, MJ. (1995). Gabapentin. *Epilepsia*. Vol. 36, Suppl 2. (1995) S57-S86. Print ISSN 0013-9580

Mecarelli, O, Li Voti, P, Pro, S, Romolo, FS, Rotolo, M, Pulitano, P, Accornero, N, Vanacore, N. (2007). Saliva and serum levetiracetam concentrations in patients with epilepsy. *Therapeutic Drug Monitoring*. Vol. 29, No. 3. (Jun 2007) 313-318. Print ISSN 0163-4356

Miles, MV, Tang, PH, Glauser, TA, Ryan, MA, Grims, SA, Strawburg, RH, deGrauw, TJ, Baumann, RJ. (2003). Topiramate concentration in saliva: an alternative to serum monitoring. *Pediatric Neurology*. Vol. 29, No. 2. (Aug 2003) 143-147. Print ISSN 0887-8994

Miles, MV, Tang, PH, Ryan, MA, Grims, SA, Fakhoury, TA, Strawburg, RH, DeGrauw, TJ, Baumann, RJ. (2004). Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). *Therapeutic Drug Monitoring*. Vol. 26, No. 3. (Jun 2004) 300-304. Print ISSN 0163-4356

Mimaki, T. (1998). Developmental and therapeutic pharmacology of antiepileptic drugs. *The Japanese Journal of Psychiatry and Neurology*. Vol. 47, No. 2. (Feb 1993) 169-174. Print ISSN 0912-2036

Morris, RG, Black, AB, Harris, AL, Batty, AB, Sallustio, BC. (1998). Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. *British Journal of Clinical Pharmacology*. Vol. 46, No. 6. (Jun 1998) 547-551. Print ISSN 0306-5251

Neels, HM, Sierens, AC, Naelerts, K, Scharpé, SL, Hatfield, GM, Lambert, WE. (2004). Therapeutic drug monitoring of old and newer anti-epileptic drugs. *Clinical Chemistry and Laboratory Medicine*. Vol. 42, No. 11. (2004) 1228-1255. Print ISSN 1434-6621

Ninomiya, H, Mamiya, K, Matsuo, S, Ieiri, I, Higuchi, S, Tashiro, N. (2000). Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. *Therapeutic Drug Monitoring*. Vol. 22, No. 2. (Apr 2000) 230-232. Print 0163-4356

Patsalos, PN. (1999). New antiepileptic drugs. *Annals of Clinical Biochemistry*. Vol. 36, No. 1. (Jan 1999) 10-19. Print ISSN 0004-5632

Patsalos, PN. (2000). Pharmacokinetic profile of levetiracetam: toward ideal characteristics. *Pharmacology and Therapeutics*. Vol. 85, No. 2. (Feb 2000) 77-85. Print ISSN 0163-7258

Patsalos, PN. (2004). Clinical pharmacokinetics of levetiracetam. *Clinical Pharmacokinetics*. Vol. 43, No. 11. (Nov 2004) 707-724. Print ISSN 0312-5963

Patsalos, PN, Berry, DJ, Bourgeois, BFD, Cloyd, JC, Glauser, TA, Johannessen, SI, Tomson, T, Perucca, E. (2008). Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. www.intechopen.com
monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. Vol. 49, No. 7. (Jun 2008) 1239-1276. Print ISSN 0013-9580

Patsalos, PN, Elyas, AA, Ratnaraj, N, Iley, J. (2002). Concentration-dependent displacement of tiagabine by valproic acid. *Epilepsia*. Vol. 43, Suppl 8. (2002) 143. Print ISSN 0013-9580

Patsalos, PN, Ghattaura, S, Ratnaraj, N, Sander, JW. (2006). In situ metabolism of levetiracetam in blood of patients with epilepsy. *Epilepsia*. Vol. 47, No. 11. (Nov 2006) 1818-1821. Print ISSN 0013-9580

Pellock, JM, Faught, E, Leppik, IE, Shinnar, S, Zupanc, ML. (2006). Felbamate: consensus of current clinical experience. *Epilepsy Research*. Vol. 71, No. 2-3. (Oct 2006) 89-101. Print ISSN 0920-1211

Pennell, PB, Peng, L, Newport, DJ, Ritchie, JC, Koganti, A, Holley, DK, Newman, M, Stowe, ZN. (2008). Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. *Neurology*. Vol. 70, No. 22 Pt 2. (2008) 2130-2136. Electronic ISSN 1526-632X

Perucca, E. (1996). Established antiepileptic drugs. *Baillieres Clinical Neurology*. Vol. 5, No. 4. (Dec 1996) 693-722. Print ISSN 0961-0421

Perucca, E. (2000). Is there a role for therapeutic drug monitoring of new anticonvulsants? *Clinical Pharmacokinetics*. Vol. 38, No. 3. (Mar 2000) 191-204. Print ISSN 0312-5963

Perucca, E. (2006). Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. *Clinical Pharmacokinetics*. Vol. 45, No. 4. 351-364. Print ISSN 0312-5963

Perucca, E, Bialer, M. (1996). The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. *Clinical Pharmacokinetics*. Vol. 31, No. 1. (Jan 1996) 29-46. Print ISSN 0312-5963

Perucca, E, Cloyd, J, Critchley, D, Fuseau, E. (2008a). Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. *Epilepsia*. Vol. 49, No. 7. (Jul 2008) 1123-1141. Print ISSN 0013-9580

Perucca, E, Yasothan, U, Clincke, G, Kirkpatrick, P. (2008b). Lacosamide. *Nature Reviews Drug Discovery*. Vol. 7, No. 12. (Dec 2008) 973-974. Print ISSN 1474-1784

Pitlick, WH, Levy, RH. (1977). Time-dependent kinetics I: Exponential autoinduction of carbamazepine in monkeys. *Journal of Pharmaceutical Sciences*. Vol. 66, No. 5. (May 1977) 647-649. Print ISSN 0022-3549

Radtke, RA. (2001). Pharmacokinetics of levetiracetam. *Epilepsia*. Vol. 42, Suppl. (2001) 24-27. Print ISSN 0013-9580

Rambeck, B, Wolf, P. (1993). Lamotrigine clinical pharmacokinetics. *Clinical Pharmacokinetics*. Vol. 20, No. 6. (Jun 1993) 433-443. Print ISSN 0312-5963

Ramsay, RE, Pellock, JM, Garnett, WR, Sanchez, RM, Valakas, AM, Wargin, WA, Lai, AA, Hubbell, J, Chern, WH, Allsup, T, et al. (1991). Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. *Epilepsy Research*. Vol. 10, No. 2-3. (Nov-Dec 1991) 191-200. Print ISSN 0920-1211

Randinitis, EJ, Posvar, EL, Alvey, CW, Sedman, AJ, Cook, JA, Bockbrader, HN. (2003). Pharmacokinetics of pregabalin in subjects with various degrees of renal functions. *Journal of Clinical Pharmacology*. Vol. 43, No. 3. (Mar 2003) 277-283. Print ISSN 0091-2700

Reimers, A, Skogvoll, E, Sund, JK, Spigset, O. (2007). Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of...
drug interactions. European Journal of Clinical Pharmacology. Vol. 63, No. 7. (Jul 2007) 687-692. Print ISSN 0031-6970

Rey, E, Pons, G, Olive, G. (1992). Vigabatrin. Clinical pharmacokinetics. Clinical Pharmacokinetics. Vol. 23, No. 4. (Apr 1992) 267-278. Print ISSN 0312-5963

Riss, J, Cloyd, J, Gates, J, Collins, S. (2008). Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurologica Scandinavica. Vol. 118, No. 2. (Aug 2008) 69-86. Print ISSN 1600-0404

Rosenfeld, WE, Doose, DR, Walker, SA, Baldassarre, JS, Reifer, RA. (1999). A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatric Neurology. Vol. 20, No. 5. (May 1999) 339-344. Print ISSN 0887-8994

Rouan, MC, Lecaillon, JB, Godbillon, J, Menard, F, Darragon, T, Meyer, P, Kourilsy, O, Hillon, D, Aldigier, JC, Jungers, P. (1994). The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. European Journal of Clinical Pharmacology. Vol. 47, No. 2. (Feb 1994) 161-167. Print ISSN 0031-6970

Ruiz, ME, Conforti, P, Fagioliino, P, Volonte, MG. (2010). The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results. Biopharmaceutics & Drug Disposition. Vol. 31, No. 8-9. (Nov 2010) 476-485. Print ISSN 0142-2782

Ryan, M, Grim, SA, Miles, MV, Tang, PH, Fakhoury, TA, Strawburg, RH, deGrauw, TJ, Baumann, RJ. (2003). Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. Vol. 23, No. 12. (Dec 2003) 1550-1557. Print ISSN 0277-0008

Sabers, A, Buchholt, JM, Uldall, P, Hansen, EL. (2001). Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Research. Vol. 47, No. 1-2. (Nov 2001) 151-154. Print ISSN 0920-1211

Sabers, A, Ohman, I, Christensen, J, Tomson, T. (2003). Oral contraceptives reduce lamotrigine plasma levels. Neurology. Vol. 61, No. 4. (Aug 26 2003) 570-571. Electronic ISSN 1526-632X

Sabers, A, Tomson, T. (2009). Managing antiepileptic drugs during pregnancy and lactation. Current Opinion in Neurology. Vol. 22, No. 2. (Apr 2009) 157-161. Print ISSN 1473-6551 (Electronic)

Sachdeo, RC, Kramer, LD, Rosenberg, A, Sachdeo, S. (1992). Felbamate monotherapy: controlled trial in patients with partial onset seizures. Annals of Neurology. Vol. 32, No. 3. (Sep 1992) 386-392. Print ISSN 0364-5134

Sachdeo, RC, Narang-Sachdeo, SKH, J.R., Dix, RK, Shumaker, RC, Perhach, JL, Rosenberg, A. (1993). Steady-state pharmacokinetics and dose-proportionality of felbamate after oral administration of 1200, 2400, and 3600 mg/day of felbamate. Epilepsia. Vol. 34, Suppl 6. (1993) 80. Print ISSN 0013-9580

Sachdeo, RC, Sachdeo, SK, Walker, SA, Kramer, LD, Nayak, RK, Doose, DR. (1996). Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. Vol. 37, No. 8. (Aug 1996) 774-480. Print ISSN 0013-9580

Schapel, G, Chadwick, D. (1996). Tiagabine and non-convulsive status epilepticus. Seizure. Vol. 5, No. 2. (Jun 1996) 153-156. Print ISSN 1059-1311

Schechter, PJ. (1989). Clinical pharmacology of vigabatrin. British Journal of Clinical Pharmacology. Vol. 27, Suppl 1. (1989) 195-225. Print ISSN 0306-5251

Selak, I. (2001). Pregabalin (Pfizer). Current Opinion in Investigational Drugs. Vol. 2, No. 6. (Jun 2001) 828-834. Print ISSN 1472-4472

www.intechopen.com
Shumaker, RC, Fantel, C, Kelton, E, Wong, K, Weliky, I. (1990). Evaluation of the elimination of (14C) felbamate in healthy men. *Epilepsia*. Vol. 31, Suppl. (1990) 642. Print ISSN 0013-9580

Sivenius, J, Kälviäinen, R, Ylinen, A, Riikkinen, P. (1991). A double-blind study of gabapentin in the treatment of partial seizures. *Epilepsia*. Vol. 32, No. 4. (Apr 1991) 539-542. Print ISSN 0013-9580

Skolnick, JL, Stoler, BS, Katz, DB, Anderston, WH. (1976). Rifampin, oral contraceptives, and pregnancy. *JAMA*. Vol. 236, No. 12. (Sep 1976) 1382. Print ISSN 0098-7484

So, EL, Wolff, D, Graves, NM, Leppik, IE, Cascino, GD, Pixton, GC, Gustavson, LE. (1995). Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. *Epilepsy Research*. Vol. 22, No. 3. (Nov 1995) 221-226. Print ISSN 0920-1211

Striano, S, Striano, P, Di Nocera, P, Italiano, D, Fasiello, C, Ruosi, P, Bilo, L, Pisani, F. (2006). Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. *Epilepsy Research*. Vol. 69, No. 2. (Jun 2006) 170-176. Print ISSN 0920-1211

Tennison, M, Ali, I, Miles, MV, D’Cruz, O, Vaughn, B, Greenwood, R. (2004). Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US Postal Service. *Therapeutic Drug Monitoring*. Vol. 26, No. 3. (Jun 2004) 295-299. Print ISSN 0163-4356

Thomas, D, Scharnecker, U, Nickel, B, Doty, P, Cavello, W, Horstmann, R. (2006). Low potential for drug-drug interaction of lacosamide. *Epilepsia*. Vol. 47 Suppl, (2006) 200. Print ISSN 0013-9580

Thompson, CD, Barthen, MT, Hopper, DW, Miller, TA, Quigg, M, Hudspeth, C, Montouris, G, Marsh, L, Perhach, JL, Sofia, RD, Macdonald, TL. (1999). Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. *Epilepsia*. Vol. 40, No. 6. (Jun 1999) 769-776. Print ISSN 0013-9580

Tomson, T, Battino, D. (2007). Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. *Clin Pharmacokinet*. Vol. 46, No. 3. (Mar 2007) 209-219. Print ISSN 0312-5963

Tran, A, Rey, E, Pons, G, Rousseau, M, d’Athis, P, Olive, G, Mather, GG, Bishop, FE, Wurden, CJ, Labroo, R, Trager, WF, Kunze, KL, Thummel, KE, Vincent, JC, Gillardin, JM, Lepage, F, Levy, RH. (1997). Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. *Clinical Pharmacology and Therapeutics*. Vol. 62, No. 5. (Nov 1997) 490-504. Print ISSN 0009-9236

Tran, A, Vauzelle-Kervroedan, F, Rey, E, Pous, G, d’Athis, P, Chiron, C, Dulac, O, Renard, F, Olive, G. (1996). Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. *European Journal of Clinical Pharmacology*. Vol. 50, No. 6. (Jun 1996) 497-500. Print ISSN 0331-6970

Tsiropoulos, I, Kristensen, O, Klitgaard, NA. (2000). Saliva and serum concentration of lamotrigine in patients with epilepsy. *Therapeutic Drug Monitoring*. Vol. 22, No. 5. (Oct 2000) 517-521. Print ISSN 0163-4356

Uthman, BM, Rowan, AJ, Ahmann, PA, Leppik, IE, Schachter, SC, Sommerville, KW, Shu, V. (1998). Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. *Archives of Neurology*. Vol. 55, No. 1. (Jan 1998) 56-62. Print ISSN 0003-9942
Van Buren, D, Wideman, CA, Ried, M, Gibbons, S, Van Buren, CT, Jarowenko, M, Flechner, SM, Frazier, OH, Cooley, DA, Kahan, BD. (1984). The antagonistic effect of rifampin upon cyclosporine bioavailability. *Transplantation Proceedings*. Vol. 16, No. 6. (Dec 1984) 1642-1645. Print ISSN 0041-1345

Vollmer, KO, von Hodenberg, A, Kölle, EU. (1988). Pharmacokinetics and metabolism of gabapentin in rat, dog and man. *Arzneimittelforschung*. Vol. 36, No. 5. (May 1988) 830-839. Print ISSN 0004-4172

Wagner, ML, Graves, NM, Marienau, K, Holmes, GB, Remmel, RP, Leppik, IE. (1991). Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. *Epilepsia*. Vol. 32, No. 3. (May-Jun 1991) 398-406. Print ISSN 0004-4172

Ward, DL, Wagner, ML, Perhach, JL, Kramer, L, Graves, N, Leppik, I, Shumaker, RC. (1991). Felbamate steady-state pharmacokinetics during co-administration of valproate. *Epilepsia*. Vol. 32, Suppl 3. (1991) 8. Print ISSN 0004-4172

Warner, A, Privitera, M, Bates, D. (1998). Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. *Clinical Chemistry*. Vol. 44, No. 5. (May 1998) 1085-1095. Print ISBN 0009-9147

Wheless, JW, Vazquez, B. (2010). Rufinamide: a novel broad-spectrum antiepileptic drug. *Epilepsy Currents*. Vol. 10, No. 1. (Jan 2010) 1-6. Print ISSN 1535-7511

Williams, J, Bialer, M, Johannessen, SI, Krämer, G, Levy, R, Mattson, RH, Perucca, E, Patsalos, PN, Wilson, JF. (2003). Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. *Epilepsia*. Vol. 44, No. 1. (Jan 2003) 40-45. Print ISSN 0013-9580

Wisniewski, CS. (2010). Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. *Annals of Pharmacotherapy*. Vol. 44, No. 4. (Apr 2010) 658-667. Print ISSN 1542-6270

Wong, MO, Eldon, MA, Keane, WF, Turck, D, Bockbrader, HN, Underwood, BA, Sedman, AJ, Halstenson, CE. (1995). Disposition of gabapentin in anuric subjects on hemodialysis. *Journal of Clinical Pharmacology*. Vol. 35, No. 6. (Jun 1995) 622-626. Print ISBN 0091-2700

Yoo, L, Matalon, D, Hoffman, RS, Goldfarb, DS. (2009). Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. *American Journal of Kidney Disease*. Vol. 54, No. 6. (Dec 2009) 1127-1130. Print ISSN 1523-6838

Zhou, C, Assem, M, Tay, JC, Watkins, PB, Blumberg, B, Schuetz, EG, Thummel, KE. (2006). Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. *Journal of Clinical Investigation*. Vol. 116, No. 6. (Jun 2006) 1703-1712. Print ISSN 0021-9738
Epilepsy continues to be a major health problem throughout the planet, affecting millions of people, mainly in developing countries where parasitic zoonoses are more common and cysticercosis, as a leading cause, is endemic. There is epidemiological evidence for an increasing prevalence of epilepsy throughout the world, and evidence of increasing morbidity and mortality in many countries as a consequence of higher incidence of infectious diseases, head injury and stroke. We decided to edit this book because we identified another way to approach this problem, covering aspects of the treatment of epilepsy based on the most recent technological results from developed countries, and the basic treatment of epilepsy at the primary care level in rural areas of South Africa. Therefore, apart from the classic issues that cannot be missing in any book about epilepsy, we introduced novel aspects related with epilepsy and neurocysticercosis, as a leading cause of epilepsy in developing countries. Many experts from the field of epilepsy worked hard on this publication to provide valuable updated information about the treatment of epilepsy and other related problems.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Matthew D. Krasowski (2011). Therapeutic Drug Monitoring of Antiepileptic Medications, Novel Treatment of Epilepsy, Prof. Humberto Foyaca-Sibat (Ed.), ISBN: 978-953-307-667-6, InTech, Available from: http://www.intechopen.com/books/novel-treatment-of-epilepsy/therapeutic-drug-monitoring-of-antiepileptic-medications
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.